| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Teleflex Incorporated$124.26
+2.59 (+2.13%)
D 31Pipeline Score MedTech · Commercial
Market Cap
5.88 B
EPS
-22.81
P/E Ratio
-
Value Trade
84.26 M
SEC Financials
Q1 2026Dilution Risk
Revenue
548.26 M
R&D Expenses
44.39 M
Operating CF
46.66 M
Total Assets
6.78 B
Total Liabilities
3.70 B
Equity
3.08 B
D/E Ratio
12,345
2.08 %
Week
-2.39 %
1 Month
19.35 %
3 Month
26.15 %
6 Month
-66.9 %
5 Year
30,579.24 %
All Time
Cash Data
Cash Position
329.55 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
407.23 K
52 Week Range
100.18 - 139.67
% held by Insiders
0.74 %
% held by Institutions
109.85 %
Enterprise Value
8.24 B
Total Shares
44.24 M
Short %
5.5 %
Float Shares
43.40 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D31
Pipeline Score $189M
Pipeline ValueValuation Signal
2
Drugs Scored0.1x
rNPV / MCap Top 30%
Small Cap (rank 634 of 905)
Percentile RankTeleflex Incorporated faces pipeline headwinds (31/100), with $290M risk-adjusted pipeline value, led by Arterial Sealing in Hemostasis of Arterial Punctures (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arterial Sealing Unknown | Hemostasis of Arterial Punctures | Phase 3 | NCT00388284 | 57% | $286M | COMPLETED | 270 | - | - | Mar 1, 2007 | - | Dec 9, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TFX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Teleflex Incorporated (TFX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TFX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TFX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TFXTeleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold
Teleflex has announced the initiation of enrollment in the global BIOMAG-III pivotal trial for its Freesolve resorbable magnesium scaffold. This trial aims to evaluate the safety and efficacy of the scaffold in patients. The move reflects Teleflex's dedication to advancing innovative medical solutions.
Read more →TFXFour‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)
The article discusses the presentation of the four-year results from the BIOMAG-I study at EuroPCR. The study confirms the long-term safety and sustained performance of the Freesolve Resorbable Magnesium Scaffold. Further details about the findings and implications for clinical practice were not provided.
Read more →TFXTeleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering
Teleflex Incorporated has announced the pricing of a $500 million senior notes offering. The offering is part of the company's strategy to raise capital. Further details regarding the terms and conditions of the offering have not been disclosed in the article.
Read more →TFXTeleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032
Teleflex Incorporated has announced a private offering of $500 million in senior notes due in 2032. The offering aims to strengthen the company's financial position. Further details regarding the use of proceeds or interest rates have not been disclosed in the announcement.
Read more →TFXLawrence Keusch Vice President, Investor Relations and Strategy Development 610-948-2836 FOR IMMEDIATE RELEASE TELEFLEX INCORPORATED ANNOUNCES PRICING OF $500
Teleflex Incorporated has announced the pricing of its private offering of $500 million in senior notes with an interest rate of 5.875%, set to mature in 2032. The offering is anticipated to close on June 15, 2026, and will be backed by its wholly-owned domestic subsidiaries. The funds raised will be used primarily to redeem existing senior notes due in 2027. The transaction is designated for qualified institutional buyers and certain non-U.S. persons, adhering to regulatory exemptions for public offerings.
Read more →TFXTeleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer
Teleflex has unveiled new clinical data at prominent urological congresses, emphasizing the benefits of the UroLift™ System in enhancing patient experiences. Additionally, the Barrigel™ Rectal Spacer has been noted for its effectiveness in reducing long-term toxicity. These findings could significantly impact treatment approaches in urology.
Read more →TFXTeleflex Reports First Quarter Financial Results and Full Year 2026 Outlook
Teleflex Incorporated reported a 32.3% increase in revenue for Q1 2026, totaling $548.3 million. Despite a loss in GAAP diluted EPS, the company maintained its revenue growth guidance for the year. The interim CEO highlighted progress in their transformation plan and the anticipated closure of strategic divestitures. The company aims to return capital to shareholders while reducing debt.
Read more →TFXTeleflex Appoints Jason Weidman as President and CEO
Teleflex Incorporated has appointed Jason Weidman as President and CEO, effective June 8, 2026. Weidman, who has over 25 years of experience in the medical technology sector, succeeds Stuart Randle, who will remain on the Board of Directors. The leadership change comes as Teleflex aims to transform its portfolio and enhance growth following significant financial strategies.
Read more →TFXTeleflex Announces First Quarter 2026 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on May 7, 2026, at 8:00 a.m. ET to discuss its first quarter financial results and provide an operational update. Participants can pre-register for the call or access it via a live audio webcast on the company's website. An audio replay will be available later that day.
Read more →TFXTeleflex Incorporated Investigated by the Portnoy Law Firm
Teleflex Incorporated is currently under investigation by the Portnoy Law Firm for possible securities fraud, following a significant drop in stock price. This decline was triggered by the sudden departure of key executives, including the Chairman, President, and CEO, Liam Kelly. The swift leadership changes have created uncertainty around the company's strategic direction, prompting the law firm to consider filing a class action on behalf of affected investors. The investigation invites investors to discuss their legal options and potential recovery of losses.
Read more →TFXTeleflex Announces Governance Updates
Teleflex Incorporated has announced significant governance updates, including the nomination of Michael J. Tokich to its Board of Directors and the formation of a new Growth and Operating Committee. The company plans to begin share repurchases ahead of schedule, reflecting its commitment to long-term value creation. The updates come as the company navigates leadership transitions and strategic transformations.
Read more →TFXIrenic Comments on Teleflex’s Announcement That It Is Open to Strategic Alternatives
Teleflex has announced that it is open to exploring strategic alternatives. This decision indicates a potential shift in the company's direction but lacks specific details on what these alternatives may entail. The announcement has generated interest among investors and market analysts, though the implications remain unclear.
Read more →TFXIrenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors
Irenic has sent a letter to the Teleflex Board of Directors expressing concern over their refusal to engage with potential acquirors. This decision could limit the company's opportunities for growth and strategic partnerships. The letter highlights the need for the board to reconsider their stance for the benefit of stakeholders.
Read more →TFXTeleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution
Teleflex has reiterated its commitment to strategies aimed at maximizing value and ensuring strong execution. The company aims to enhance its operational effectiveness and drive growth through these initiatives. However, specific details regarding the strategies or their anticipated impact were not provided in the article.
Read more →TFXTeleflex Announces Quarterly Dividend
Teleflex Incorporated has announced a quarterly cash dividend of $0.34 per share, which will be payable on March 31, 2026. Shareholders of record as of March 6, 2026, will be eligible for this dividend. The announcement highlights Teleflex's ongoing commitment to shareholder value.
Read more →TFXTeleflex Reports 2025 Financial Results and Full Year 2026 Outlook
Teleflex Incorporated announced its financial results for 2025 and provided guidance for 2026, expecting mid-single-digit revenue growth. The company is undergoing a transformation with strategic divestitures and a restructuring plan aimed at reducing stranded costs. The restructuring is projected to yield annual pre-tax savings of $48 million to $52 million, enhancing long-term shareholder value.
Read more →TFXTeleflex Announces Fourth Quarter 2025 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on February 26, 2026, at 8:00 a.m. ET to discuss its fourth quarter 2025 financial results and provide an operational update. Participants can pre-register for the call and access it via a live audio webcast. An audio replay will be available later that day.
Read more →TFXTeleflex Announces Leadership Transition Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminar
Teleflex Incorporated announced a leadership transition with Stuart Randle appointed as Interim President and CEO, succeeding Liam Kelly. The company is initiating a search for a permanent CEO while Dr. Stephen Klasko has taken on the role of Chairman of the Board. In addition, Teleflex provided a preliminary update on its revenue expectations for 2025, forecasting $3.270 billion to $3.278 billion, a decrease from prior estimates due to softer market demand and order delays. The financial outlook highlights challenges, particularly in the U.S. and Asia markets for certain products.
Read more →TFXTeleflex Announces Leadership Transition
Teleflex Incorporated has announced a leadership transition, appointing Stuart Randle as Interim President and CEO following the departure of Liam Kelly. Dr. Stephen Klasko has taken over as Chairman of the Board as the company embarks on a focused strategy after the sale of several business segments. In addition, the company provided an update on its preliminary revenue results for 2025, indicating a reduction from previous guidance due to weak demand and order delays. Full fourth quarter and year-end results are expected to be reported in early 2026.
Read more →TFXTeleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion
Teleflex Incorporated has announced the sale of its Acute Care, Interventional Urology, and OEM businesses for $2.03 billion. This strategic move aims to streamline operations and enhance growth in core markets. The transactions are expected to close in the second half of 2026, pending regulatory approvals. Proceeds will primarily be used for shareholder returns and debt reduction.
Read more →TFXTeleflex to Present at the Jefferies Global Healthcare Conference in London
Teleflex Incorporated is scheduled to present at the Jefferies Global Healthcare Conference in London on November 18, 2025. The presentation will be available via a live audio webcast on the company's investor website. Teleflex emphasizes its commitment to improving healthcare through innovative medical technologies.
Read more →TFXTeleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook
Teleflex Incorporated reported its third quarter financial results for 2025, highlighting adjusted earnings per share and operating margins that surpassed expectations. However, the company faced challenges with lower order rates for its intra-aortic balloon pump portfolio. Additionally, significant non-cash impairment charges were recognized, impacting overall financial outlook. The company is actively working on separating its business into two entities and integrating the Vascular Intervention business.
Read more →TFXTeleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
Teleflex Incorporated will hold a conference call on November 6, 2025, to discuss its third quarter financial results and provide operational updates. Additionally, a virtual meeting on November 14, 2025, will review the company's recent acquisition in the Vascular Intervention sector. Interested participants can pre-register for both events via the company's website.
Read more →TFXFirst Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients
Teleflex Incorporated has announced the enrollment of the first patient in the DUBSTENT DIABETES trial, which aims to evaluate a dual-device strategy for percutaneous coronary intervention in diabetic patients. The trial will compare the efficacy of combining drug-coated balloon angioplasty with drug-eluting stent implantation against single-device strategies. This study addresses the high rates of stent failure in diabetic patients and aims to improve long-term vessel health.
Read more →TFXTeleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Teleflex Incorporated will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The presentation is scheduled for 3:20 p.m. (ET) at the Sheraton New York Times Square. A live audio webcast will be available on their investor website, emphasizing their commitment to transparency and engagement with stakeholders.
Read more →TFXTeleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy
Teleflex has launched the Barrigel™ rectal spacer in Japan, following regulatory approval. This innovative product aims to minimize rectal toxicity during prostate radiation therapy, making it a significant advancement in cancer treatment. Initial cases have been performed successfully, and the company is committed to educating healthcare professionals about its benefits. This launch marks a key milestone in Teleflex's global expansion strategy.
Read more →TFXTeleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook
Teleflex Incorporated has announced its financial results for the second quarter of 2025, revealing a 4.2% increase in revenue and a rise in GAAP diluted EPS to $2.77. The company has raised its guidance for revenue growth and earnings per share for the full year, citing the recent acquisition of BIOTRONIK's Vascular Intervention business as a driving factor. This acquisition is expected to enhance Teleflex's portfolio in the peripheral intervention market. Overall, the results reflect a positive trajectory for the company's financial performance in the current year.
Read more →TFXTeleflex Announces Second Quarter 2025 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on July 31, 2025, at 8:00 a.m. ET to discuss its second quarter financial results and provide an operational update. Participants can pre-register for the call or access it via a live audio webcast on the company's website. An audio replay will be available later that day.
Read more →TFXTeleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business
Teleflex has successfully completed the acquisition of BIOTRONIK's Vascular Intervention business, enhancing its portfolio with a range of therapeutic products. This acquisition positions Teleflex to expand its presence in the cath lab and peripheral intervention market. The deal, valued at €760 million, is expected to generate significant revenue growth and improve patient care through innovative technologies.
Read more →TFXTeleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month
Teleflex has launched two public initiatives during Men's Health Month to raise awareness about benign prostatic hyperplasia (BPH) and its impact on men's quality of life. The Prostate Monster ad campaign and the Prostate Education Express mobile education center aim to educate men and healthcare providers about treatment options like the UroLift System and the Barrigel rectal spacer. These initiatives will tour major U.S. cities, promoting understanding and encouraging proactive healthcare management among the male population. The program highlights the importance of addressing BPH symptoms to improve overall health and well-being.
Read more →TFXTeleflex Incorporated Announcement: If You Have Suffered Losses in Teleflex Incorporated (NYSE: TFX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm has announced an investigation into Teleflex Incorporated for potential securities claims. Shareholders are encouraged to learn about their rights due to allegations of materially misleading business information. Following a significant drop in Teleflex's stock price after its split announcement and a related article, investors may be entitled to compensation through a class action. The firm offers services without fees until compensation is secured, highlighting its track record in securities class actions.
Read more →TFXTeleflex Publishes 2024 Global Impact Report
Teleflex Incorporated has released its 2024 Global Impact Report, highlighting significant strides in its Corporate Social Responsibility initiatives. The report details the company's accomplishments across four main pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance. Notable features include a materiality assessment aligned with EU regulations and commitments to equitable healthcare access. The company also showcased progress in its environmental practices, particularly concerning greenhouse gas emissions management.
Read more →TFXTeleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting
Teleflex Incorporated presented new clinical data at the 2025 AUA Annual Meeting, highlighting the UroLift System's advantages for treating benign prostatic hyperplasia (BPH). Two randomized trials demonstrated superior early patient satisfaction and symptom relief compared to traditional treatments such as Rezum and tamsulosin. Additionally, the safety of the stabilized hyaluronic acid rectal spacer was confirmed, indicating its minimal risk for complications during prostate cancer treatment. The findings reinforce Teleflex's commitment to evidence-based innovation in urology.
Read more →TFXTeleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
Teleflex Incorporated reported a decrease in first-quarter revenues for 2025, totaling $700.7 million, a decline of 5.0% year-over-year. Despite this, the Company raised its GAAP revenue growth guidance for the year and maintained its adjusted constant currency revenue projections. However, it also lowered its earnings per share (EPS) guidance due to anticipated tariff impacts and related costs. The Company continues to explore options for its planned separation into independent entities.
Read more →TFXTeleflex receives FDA 510(k) Clearance for Expanded Indications of the QuikClot Control+™ Hemostatic Device
Teleflex Incorporated announced that the U.S. FDA has granted 510(k) clearance for expanded indications of its QuikClot Control+™ Hemostatic Device. The device can now be used for controlling all grades of internal and external bleeding, significantly broadening its application beyond the previous limitations. This change is expected to enhance clinical outcomes in various surgical procedures and is estimated to increase the company's addressable market by over $150 million. The clearance was supported by real-world evidence from an observational study, confirming the device's effectiveness in diverse clinical settings.
Read more →TFXTeleflex to Present at the BofA Securities 2025 Health Care Conference
Teleflex Incorporated will be presenting at the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. A live audio webcast of the presentation will be accessible on the company's investor section of its website. Teleflex is recognized for its emphasis on improving healthcare and offers a variety of medical technologies across multiple therapy areas.
Read more →TFXTeleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting
Teleflex Incorporated announced the presentation of multiple clinical studies at the upcoming 2025 American Urological Association Annual Meeting. These studies focus on innovations in the treatment of benign prostatic hyperplasia (BPH) and the use of rectal spacers during radiation for prostate cancer. A key highlight includes findings from the CLEAR Randomized Controlled Trial, which compares outcomes between the UroLift and Rezum treatments. Additionally, Teleflex will host several educational events aimed at enhancing physician knowledge and patient care in urology.
Read more →TFXTeleflex Announces First Quarter 2025 Earnings Conference Call Information
Teleflex Incorporated will conduct a conference call on May 1, 2025, to discuss its financial results for the first quarter of 2025. The call, starting at 8:00 a.m. Eastern Time, will provide an operational update for investors and interested stakeholders. Participants can pre-register to receive dial-in information or access a live audio webcast via the company's website. An audio replay of the call will be available after it concludes.
Read more →TFXTeleflex Receives FDA 510(k) Clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP)
Teleflex Incorporated has received FDA 510(k) clearance for its AC3 Range™ Intra-Aortic Balloon Pump, designed for reliable support during patient transport. This device incorporates advanced technology from the AC3 Optimus™ IABP and features tailored for transport challenges. It will begin shipping in the second quarter of 2025. Teleflex aims to showcase the device at the upcoming ISHLT Annual Meeting in Boston, highlighting its importance in cardiac patient care.
Read more →TFXTeleflex Announces Updated Clinical Study Data Presented at the European Association of Urology (EAU) Congress
Teleflex Incorporated has presented updated findings from its CLEAR study at the EAU Congress, illustrating the UroLift System's superiority over Rezum Water Vapor Therapy for treating benign prostatic hyperplasia. The study highlights significantly higher patient satisfaction and improved sexual function for those using the UroLift System. Additionally, UroLift patients experienced fewer complications and a quicker recovery time, reinforcing its position as a preferred treatment option. These insights are expected to guide both clinician and patient decision-making processes regarding treatment options for BPH.
Read more →TFXTeleflex to Acquire BIOTRONIK’s Vascular Intervention Business
Teleflex Incorporated announced a definitive agreement to acquire BIOTRONIK's Vascular Intervention business for approximately €760 million, which will significantly enhance its portfolio in the interventional cardiology market. The acquisition aims to expand Teleflex's offerings of vascular intervention devices, including drug-coated balloons and stents, and is anticipated to be completed by the end of Q3 2025, pending regulatory approvals. With about 75% of the acquired revenues derived from coronary interventions, the acquisition is expected to bolster Teleflex's global growth strategy, providing an opportunity for innovation and diversification in geographic revenue sources.
Read more →TFXTeleflex Announces Intent to Separate into Two Publicly Traded Companies
Teleflex Incorporated plans to separate its Urology, Acute Care, and OEM businesses into a new independent entity named 'NewCo'. Following the separation, RemainCo will focus on high-growth and hospital-centric market segments. The transaction is anticipated to be tax-free for U.S. shareholders and aims to optimize both companies' operational capabilities and growth potential. The official separation completion is projected for mid-2026.
Read more →TFXTeleflex Reports Fourth Quarter and Full Year 2024 Financial Results
Teleflex Incorporated reported its financial results for the fourth quarter and full year 2024, revealing a revenue increase of 2.8% in Q4. The company saw a significant drop in GAAP diluted EPS, which reached $(2.95), despite an increase in adjusted EPS to $3.89. Looking ahead, Teleflex provided guidance for 2025 indicating a potential minimal revenue growth, while announcing plans for a major acquisition of BIOTRONIK's Vascular Intervention business and a corporate separation into two public entities. These steps aim to enhance operational focus and product diversity.
Read more →TFXTeleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer
Teleflex Incorporated announced the planned retirement of Chief Financial Officer Thomas E. Powell, effective April 1, 2025. John R. Deren, currently the Corporate Vice President and Chief Accounting Officer, will assume the CFO role on April 2, 2025. Powell, who has been with the company for over 13 years, will continue to support Teleflex as a consultant until March 31, 2026, to ensure a smooth transition in its financial leadership.
Read more →TFXTeleflex to Present at the Raymond James & Associates 46th Annual Institutional Investors Conference
Teleflex Incorporated is set to present at the Raymond James & Associates 46th Annual Institutional Investors Conference on March 4, 2025. The presentation will take place at the JW Marriott Grande Lakes in Orlando, Florida, and will be available as a live audio webcast. This event allows Teleflex to connect with institutional investors and showcase its diverse portfolio in medical technologies.
Read more →TFXTeleflex Announces Fourth Quarter 2024 Earnings Conference Call Information
Teleflex Incorporated will conduct a conference call on February 27, 2025, to discuss its fourth quarter financial results and provide an operational update. The call will begin at 8:00 a.m. Eastern Time, and participants can pre-register to receive dial-in information. A replay of the call will be available later that day through both a telephone service and the company's website. Teleflex is known for its extensive range of medical technologies and brands.
Read more →TFXTeleflex awarded Short Term Central Venous Catheters contract from Vizient
Teleflex Incorporated has secured a contract with Vizient, effective January 1, 2025, to supply Central Venous Access Catheters and Arterial Catheters. This partnership will enhance access to cost-effective vascular access products for Vizient's healthcare provider network. Teleflex's portfolio includes the Arrowg+ard Blue Plus CVCs, which significantly decrease the risk of Central Line-Associated Bloodstream Infections. The agreement emphasizes collaboration to improve patient outcomes and standardize practices in acute care settings.
Read more →TFXTeleflex to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Teleflex Incorporated (NYSE: TFX) is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. Liam Kelly, the Chairman, President and CEO, will be speaking at the event in San Francisco. A live audio webcast will be available for those unable to attend in person. This presentation highlights Teleflex's dedication to improving healthcare through innovative medical technologies.
Read more →TFXTeleflex to Present at the 36th Annual Piper Sandler Healthcare Conference
Teleflex Incorporated will present at the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024. Chairman and CEO Liam Kelly is scheduled to speak at 9:30 a.m. ET during the event, which will be held at The Lotte New York Palace in New York City. The conference presentation will be accessible via a live audio webcast on Teleflex's investor relations website. This event highlights Teleflex's ongoing commitment to healthcare innovation and partnership.
Read more →TFXTeleflex to Present at the Jefferies London Healthcare Conference
Teleflex Incorporated, represented by its Chairman and CEO Liam Kelly, will present at the Jefferies London Healthcare Conference on November 21, 2024. A live audio webcast of the presentation will be accessible on the investor section of the Teleflex website. The company emphasizes its commitment to healthcare improvement and innovation through its diverse portfolio of medical technologies.
Read more →TFXTeleflex Reports Third Quarter Financial Results and Full Year 2024 Outlook
Teleflex Incorporated reported its financial results for the third quarter of 2024, showing a revenue increase of 2.4% year-over-year. While the company raised its adjusted EPS guidance, it also lowered its revenue growth expectations for the full year, highlighting challenges in the OEM segment. The CEO noted strong revenue from Vascular Access and Interventional categories, which helped to offset some of the difficulties faced. Overall, the financial outlook remains cautiously optimistic due to improvements in cash flow and margin expansion.
Read more →TFXTeleflex launches next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet in Canada
Teleflex Incorporated has announced the launch of its next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet in Canada. These devices aim to enhance peripherally inserted central catheter (PICC) insertion procedures and minimize complications by providing real-time location information and improved catheter navigation. Research with vascular access professionals contributed to the design enhancements, leading to promising results in initial testing. The company emphasizes its commitment to reducing catheter-related complications in collaboration with healthcare providers.
Read more →TFXTeleflex Announces Third Quarter 2024 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on October 31, 2024, at 8:00 a.m. Eastern Time to discuss its third quarter financial results and provide an operational update. Participants can pre-register to receive dial-in information or join a live audio webcast through Teleflex's website. An audio replay will be available after the call. Teleflex emphasizes its commitment to improving healthcare through a diverse portfolio of medical technologies.
Read more →TFXTeleflex’s Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting
Teleflex Incorporated announced that its Barrigel rectal spacer will be featured in three presentations at the upcoming 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. The presentations will highlight new safety and efficacy data, supporting Barrigel’s role in reducing rectal radiation exposure during prostate cancer treatment. Additionally, Teleflex will hold an educational symposium discussing personalized approaches to using Barrigel. The product is designed to enhance the quality of life for prostate cancer patients while undergoing radiation therapy.
Read more →TFXTeleflex to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Teleflex Incorporated is scheduled to present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024. Liam Kelly, the company's Chairman, President, and CEO, will lead the presentation. Teleflex, recognized for its diverse medical technology solutions, emphasizes its commitment to enhancing the health and quality of people's lives. A live audio webcast of the event will be available on the company's investor relations website.
Read more →TFXTeleflex Announces Publication of a Propensity Matching Review of Retrospective Data Reporting that the Titan SGS™ Stapler Enables Consistent Gastric Pouch Formation with Fewer Variations, Providing Potentially Enhanced Clinical Outcomes and Significant Procedural Efficiency Compared with Traditional Surgical Staplers
Teleflex Incorporated has published a study highlighting the advantages of its Titan SGS™ Stapler for laparoscopic sleeve gastrectomy (LSG). This retrospective analysis involved a significant patient cohort and demonstrated considerable enhancements in clinical outcomes, including fewer readmissions and shorter hospital stays compared to traditional multi-fire staplers. The results shared in 'Obesity Surgery' indicate that the Titan SGS™ Stapler reduces procedural risks associated with overlapping staple lines. Moreover, the device is recognized as the only stapler specifically designed and cleared by the FDA for this surgical indication.
Read more →TFXTeleflex Reports Second Quarter Financial Results and Full Year 2024 Outlook
Teleflex Incorporated reported its second quarter financial results for 2024, showing a modest revenue increase of 0.9% year-over-year to $749.7 million. Despite a decrease in GAAP diluted EPS from $2.35 to $1.69, the company raised its adjusted revenue growth guidance for the full year. Teleflex also announced a $500 million share repurchase program, indicating confidence in future growth. The overall results reflect a strategic focus on durable revenue growth amid various challenges.
Read more →TFXTeleflex Expands Interventional Cardiology Portfolio with FDA 510(k) Clearance of the Ringer™ Perfusion Balloon Catheter
Teleflex Incorporated announced FDA 510(k) clearance for its Ringer Perfusion Balloon Catheter, which is designed for use in Percutaneous Transluminal Coronary Angioplasty procedures. This unique catheter allows continuous blood flow during balloon inflation, aimed at improving myocardial perfusion in patients. The device is set for a limited market release in August 2024. The clearance represents a significant advancement in interventional cardiology technology, underscoring Teleflex's commitment to innovation and patient safety.
Read more →TFXTeleflex Awarded Hemostasis Products Agreements with Premier, Inc.
Teleflex Incorporated has been awarded two significant group purchasing agreements with Premier, Inc., effective July 1, 2024. These agreements will allow Premier members to access pre-negotiated pricing for Teleflex's hemostatic products, including the QuikClot line, designed to improve bleeding control in various clinical settings. The collaboration aims to standardize purchasing decisions and offer cost savings across Premier's network of member hospitals and healthcare providers. This partnership underscores Teleflex's commitment to enhancing patient care through innovative medical technologies.
Read more →TFXTeleflex Announces the Teleflex Center for Antimicrobial Protection
Teleflex Incorporated has announced the launch of the Teleflex Center for Antimicrobial Protection (TCAP) located in Research Triangle, North Carolina. This center is dedicated to combating infections caused by multidrug-resistant organisms, aiming to educate and assist healthcare professionals and patients alike. Teleflex emphasizes its commitment to innovative vascular access products and showcases its comprehensive portfolio of antimicrobial catheters designed to reduce infection risk. TCAP aims to improve healthcare outcomes by pioneering advances in catheter protection technology.
Read more →TFXTeleflex Announces Second Quarter 2024 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on August 1, 2024, at 8:00 a.m. Eastern Time to discuss its second quarter financial results and provide an operational update. Participants can pre-register for dial-in information or access the call via a live audio webcast on the company's website. An audio replay will be available shortly after the call concludes.
Read more →TFXTeleflex Publishes 2023 Global Impact Report
Teleflex Incorporated has published its 2023 Global Impact Report, outlining significant achievements in its Corporate Social Responsibility (CSR) program. The report details commitments to net-zero greenhouse gas emissions by 2050 and highlights improvements in Environmental, Social, and Governance (ESG) ratings. Additionally, Teleflex has generated over 7.5 GWh of renewable electricity at its manufacturing sites and issued substantial research grants totaling $8.5 million. The report emphasizes the company’s focus on products, patients, and environmental stewardship.
Read more →TFXTeleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray
Teleflex Incorporated has launched the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray, enhancing its intraosseous vascular access portfolio. The tray includes a battery-powered driver and various components for quick and sterile access procedures. Clinicians reported difficulties in rapid vascular access, thus introducing a single-use tray aims to address these challenges. This innovation is expected to improve efficiency and convenience in emergency medical situations.
Read more →TFXTeleflex Reports First Quarter Financial Results and Full Year 2024 Outlook
Teleflex Incorporated reported its first quarter financial results for 2024, showing a revenue increase of 3.8% year-over-year, totaling $737.8 million. The company adjusted its earnings per share guidance upwards, anticipating a range of $6.87 to $7.22 for GAAP EPS. However, it also lowered its overall GAAP revenue growth forecast to a range of 3.35% to 4.35%, primarily due to foreign exchange rate fluctuations. The results indicate solid performance across several segments, particularly in EMEA and Asia, but also reveal challenges in the Americas region.
Read more →TFXTeleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
Teleflex Incorporated announced the presentation of several clinical studies at the 2024 American Urological Association Annual Meeting in San Antonio, TX. The studies will highlight the UroLift™ System versus traditional treatments for benign prostatic hyperplasia (BPH), emphasizing its efficacy and safety. The UroLift™ 2 System, recently FDA-approved, features advanced technology aimed at enhancing procedural accuracy and physician comfort. These presentations aim to further solidify the UroLift™ System's role in improving patient outcomes associated with BPH treatments.
Read more →TFXTeleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire
Teleflex Incorporated has begun the limited market release of the Wattson™ Temporary Pacing Guidewire aimed at enhancing structural heart procedures. The device, engineered for optimal dual functionality, received FDA clearance in May 2023 and is being implemented in procedures at Columbia University Irving Medical Center. Initial feedback from cardiologists indicates satisfactory performance in facilitating transcatheter aortic valve replacement (TAVR) with reliable pacing capabilities. This release marks a significant advancement in Teleflex's structural heart portfolio.
Read more →TFXTeleflex to Present at the BofA Securities 2024 Health Care Conference
Teleflex Incorporated, a global provider of medical technologies, is set to present at the BofA Securities 2024 Health Care Conference. CEO Liam Kelly will speak at the conference on May 14, 2024, at 2:20 p.m. PT. The event will be held at the Encore Hotel in Las Vegas, and a live audio webcast of the presentation will be available on the company’s investor website. This appearance highlights Teleflex's dedication to shareholder engagement and innovation in healthcare.
Read more →TFXTeleflex Announces First Quarter 2024 Earnings Conference Call Information
Teleflex Incorporated is set to host a conference call on May 2, 2024, to discuss its first quarter financial results and provide an operational update. Interested participants can pre-register to receive dial-in information or access the call via a live audio webcast on Teleflex's official website. An audio replay will be available later the same day for those who cannot join the live session. The company emphasizes its dedication to developing medical technologies that enhance patient care.
Read more →TFXTeleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
Teleflex Incorporated announced the market release of its UroLift™ 2 System featuring Advanced Tissue Control (ATC) for the treatment of benign prostatic hyperplasia (BPH). This updated system, which has received FDA clearance, offers enhanced precision and customization for physicians treating various prostate types. The UroLift™ 2 ATC aims to improve patient care by streamlining procedures and ensuring the system is readily available during treatments. Physicians reported increased confidence and effectiveness in managing enlarged prostate symptoms with this innovative technology.
Read more →TFXTeleflex’s Climate Targets Validated by the Science Based Targets Initiative
Teleflex Incorporated has announced that its climate change targets have been validated by the Science Based Targets initiative (SBTi), committing to reduce greenhouse gas emissions significantly. The company aims for net-zero GHG emissions by 2050 and plans to reduce its emissions by 54.6% by 2032. The SBTi's validation emphasizes Teleflex's commitment to sustainability and corporate social responsibility. This announcement precedes the release of Teleflex's 2023 Global Impact Report, expected in May 2024.
Read more →TFXThe release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on
Teleflex Incorporated discussed its Q4 2023 earnings and provided guidance for 2024 in a conference call. The company reported a revenue growth of 2.1% year-over-year and an adjusted EPS of $3.38, despite a decline from the previous year. The performance was supported by product launches and a stable macroeconomic environment, yet operational margins experienced a significant decline. The company continues to focus on durable growth as it enters 2024, emphasizing its diversified portfolio and ongoing integration of Palette Life Sciences.
Read more →TFXTeleflex Reports Fourth Quarter and Full Year 2023 Financial Results
Teleflex Incorporated published its financial results for Q4 and the full year 2023, reporting a 6.6% increase in revenues year-over-year. However, GAAP diluted EPS from continuing operations fell from $1.65 to $0.66 during the fourth quarter. For 2024, the company forecasts revenue growth between 3.60% to 4.60% and adjusted EPS growth of up to 3.2%. Despite challenges, Teleflex emphasized its ongoing commitment to corporate growth strategies and integration of recent acquisitions.
Read more →TFXTeleflex to Present at the 45th Annual Raymond James Institutional Investors Conference
Teleflex Incorporated has announced that Liam Kelly, its Chairman, President, and CEO, will speak at the 45th Annual Raymond James Institutional Investors Conference on March 5, 2024. The event will take place at the JW Marriott Orlando Grande Lakes, and a live audio webcast of the presentation will be accessible on the company's investor relations website. Teleflex is recognized as a global provider of medical technologies across various healthcare sectors.
Read more →TFXTeleflex Announces Fourth Quarter 2023 Earnings Conference Call Information
Teleflex Incorporated, a global provider of medical technologies, announced it will hold a conference call on February 22, 2024, to discuss its fourth quarter financial results and provide an operational update. The call is aimed at enhancing investor communication and can be accessed via a live audio webcast or dial-in. An audio replay will also be available shortly after the call.
Read more →TFXTeleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement
Teleflex Incorporated has announced the availability of its Titan SGS™ Stapler with a new staple line reinforcement option, which received FDA 510(k) clearance. This stapler is specifically designed for sleeve gastrectomy procedures in bariatric surgery. The enhancement aims to improve staple line strength and decrease the incidence of leaks and bleeds, thereby providing surgeons with innovative tools that may improve patient outcomes. Over 10,000 procedures have been performed using the Titan SGS™ Stapler since its introduction in 2021, bolstering confidence in its efficacy and safety.
Read more →TFXTeleflex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Teleflex Incorporated CEO Liam Kelly is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, in San Francisco. The presentation will be accompanied by a live audio webcast and slides, accessible via the Teleflex investor section on their website. Teleflex focuses on improving health through innovative medical technologies across various specialties, which underscores their commitment to addressing unmet clinical needs.
Read more →TFXTeleflex Awarded Peripheral Access Agreement with Premier, Inc.
Teleflex Incorporated has secured a Peripheral Access purchasing agreement with Premier, Inc., effective December 1, 2023. This agreement provides Premier members access to specially priced Teleflex products, including Peripherally Inserted Central Catheters (PICCs) and navigation equipment. The collaboration aims to optimize vascular access solutions, enhance patient safety, and reduce infection risks. Teleflex is committed to delivering innovative medical technologies to meet the needs of healthcare providers and patients alike.
Read more →TFXTeleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
Teleflex has announced the first patient enrollment in the ACCESS-MANTA™ Registry aimed at evaluating the MANTA™ Vascular Closure Device's performance during transcatheter aortic valve replacement (TAVR) procedures. This international registry will recruit a minimum of 250 patients across 15 major institutions in the US and Canada to gather data on safety and effectiveness. The study intends to assess various factors including vascular complications and procedural success, reflecting advancements in TAVR practices. Notably, the participation of renowned medical centers enhances the study's potential impact on clinical practices.
Read more →TFXTeleflex to Present at the 35th Annual Piper Sandler Healthcare Conference
Teleflex Incorporated (NYSE: TFX) will be represented by Liam Kelly, Chairman, President and CEO, at the 35th Annual Piper Sandler Healthcare Conference. The event is scheduled for November 28, 2023, in New York City. Attendees can access a live audio webcast of the presentation through the investor section of the Teleflex website. Teleflex is recognized for its commitment to medical technology innovations aimed at improving health quality and addressing unmet clinical needs.
Read more →TFXTeleflex Reports Third Quarter Financial Results and Full Year 2023 Outlook
Teleflex Incorporated (NYSE: TFX) announced strong financial results for Q3 2023, with a revenue increase of 8.7% year-over-year. The company raised its revenue and earnings guidance for the full year, reflecting a favorable performance in its surgical and interventional markets, particularly in the Asia Pacific region. The CEO highlighted the company’s recent acquisition of Palette Life Sciences AB, aimed at enhancing their product offerings. However, Teleflex also noted potential revenue impacts from an earlier-than-planned termination of certain service agreements.
Read more →TFXTeleflex Announces Third Quarter 2023 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on November 2, 2023, at 8:00 a.m. ET to discuss its third quarter financial results and provide an operational update. Participants can pre-register for the call and access it through a live audio webcast on the company's website. A replay of the call will be available shortly after it concludes, ensuring stakeholders can stay informed about the company's performance.
Read more →TFXTeleflex Completes Acquisition of Palette Life Sciences
Teleflex Incorporated has successfully completed its acquisition of Palette Life Sciences AB, enhancing its Interventional Urology portfolio with the addition of Barrigel®, a rectal spacer designed to improve radiation therapy outcomes for prostate cancer patients. The acquisition includes an upfront payment of $600 million and is expected to impact adjusted earnings per share negatively in the near term, with projected revenue growth for Palette in the coming years. Teleflex anticipates the transaction will become increasingly accretive to earnings over time.
Read more →TFXTeleflex Selected to Exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at Vizient Innovative Technology Exchange
Teleflex Incorporated has been selected to exhibit its Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at the Vizient Innovative Technology Exchange taking place on October 3 in Grapevine, Texas. This event allows suppliers to present products aimed at improving clinical outcomes to leaders in healthcare. The technologies showcased by Teleflex aim to enhance the efficiency and safety of PICC placements, which are essential for vascular access specialists.
Read more →TFXTeleflex to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Teleflex Incorporated's CEO, Liam Kelly, is scheduled to present at the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023. The presentation will take place at the Sheraton New York and will be accessible via a live audio webcast on Teleflex's investor website. This event marks an opportunity for Teleflex to showcase its innovations and address unmet clinical needs in the healthcare sector.
Read more →TFXTeleflex Announces Extension of Arrow™ ErgoPack™ Complete System to Hemodialysis and Large Bore Central Venous Catheters
Teleflex Incorporated announced the launch of the Arrow™ ErgoPack™ Complete Kits with hemodialysis and large bore catheters in the U.S., designed to improve clinician workflow. The kits now offer various configurations, including clinician-inspired updates like a tactile GlideWheel™ Advancer and kink-resistant Nitinol Guidewire. This expansion aims to enhance safety during central line insertions and align with established clinical guidelines for infection prevention.
Read more →TFXTeleflex Reports Second Quarter Financial Results and Full Year 2023 Outlook
Teleflex Incorporated has reported a strong financial performance for the second quarter of 2023, with revenues of $743.3 million, marking a 5.5% increase year-over-year. The company raised its revenue growth guidance for the full year, reflecting confidence in its diversified product portfolio and stable market conditions. However, it has lowered its guidance for GAAP EPS from continuing operations to between $7.33 and $7.93. Notably, the acquisition of Palette Life Sciences AB is expected to significantly contribute to growth, expanding Teleflex's offerings in interventional urology.
Read more →TFXTeleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+™ Hemostatic Device Usage in Cardiac Surgical Procedures
Teleflex Incorporated has received FDA clearance for its QuikClot Control+ Hemostatic Device, now approved for mild and moderate bleeding during cardiac surgical procedures. This expanded indication aims to provide surgeons with an effective solution for intraoperative bleeding control, particularly in over 600,000 procedures performed annually in the U.S. The device has shown superior performance in achieving clinical hemostasis compared to standard gauze, improving patient safety and outcomes. Teleflex anticipates that this development will significantly benefit cardiovascular and cardiothoracic surgeons.
Read more →TFXTeleflex to Acquire Palette Life Sciences
Teleflex Incorporated has announced its definitive agreement to acquire Palette Life Sciences AB for $600 million, with an additional $50 million contingent on commercial milestones. This acquisition aims to enhance Teleflex's Interventional Urology portfolio with innovative products such as Barrigel®, which improves patient outcomes in various medical applications. The acquisition is expected to close in Q4 2023, subject to regulatory approvals. While it is anticipated to boost growth in the coming years, it may temporarily dilute earnings per share in the immediate term.
Read more →TFXTeleflex Awarded National Group Purchasing Agreements with Premier, Inc.
Teleflex Incorporated announced the award of three group purchasing agreements with Premier, Inc., effective August 1, 2023. These agreements will allow Premier members to access special pricing on selected Teleflex products, specifically within the categories of Laryngoscope Systems, Laryngeal Masks Airways, and Disposable Anesthesia Products. The collaboration aims to enhance the availability of Teleflex's market-leading Airway Management solutions, ultimately contributing to better healthcare outcomes for patients.
Read more →TFXTeleflex Announces Second Quarter 2023 Earnings Conference Call Information
Teleflex Incorporated has announced a conference call scheduled for 8:00 a.m. Eastern Time on August 3, 2023, to discuss its second quarter financial results and operational updates. Investors can pre-register to access the call or listen via a live audio webcast on Teleflex's website. An audio replay of the call will be available later for those who cannot attend. The company continues to focus on innovative medical technologies that improve healthcare quality.
Read more →TFXTeleflex Completes Enrollment in Percutaneous Coronary Intervention Study
Teleflex Incorporated has completed enrollment in the multicenter RingerTM PTCA study, which evaluates the RingerTM Perfusion Balloon Catheter's performance in coronary interventions. This milestone is critical for the clinical validation needed for regulatory approval. The study, conducted across seven leading PCI centers in the US and Canada, aims to provide continued perfusion during balloon inflations. In parallel, a separate study is assessing RingerTM's utility in managing coronary perforations, a serious complication during PCI procedures.
Read more →TFXTeleflex Announces Partnership with Insighters Medical for Exclusive Distribution of the Insighters Video Laryngoscope System
Teleflex Incorporated has announced an exclusive partnership with Shenzhen Insighters Medical Technology to distribute the Insighters® Video Laryngoscope system in the U.S. This system aids in inspecting the upper glottic airway and facilitates endotracheal intubation through real-time high-resolution imaging. The new device enhances Teleflex's existing airway management portfolio and aligns with best practices for navigating difficult intubation scenarios. The announcement signals an effort to improve clinical outcomes in anesthesia and emergency medicine.
Read more →TFXTeleflex Receives FDA Clearance for the Wattson Temporary Pacing Guidewire
Teleflex Incorporated has received FDA clearance for its Wattson® Temporary Pacing Guidewire, the first bipolar temporary pacing guidewire specifically designed for TAVR and BAV procedures. This guidewire features a simple design aimed at creating procedural efficiencies, while providing dual functionality that supports both valve delivery and ventricular pacing. It helps to reduce risks associated with traditional methods, such as ventricular perforation, and will be introduced in a limited market release phase before a full launch later this year.
Read more →TFXTeleflex Announces the Arrow EZ-IO Needle Is Now FDA Cleared For Use in an MRI Environment
Teleflex Incorporated has announced that its Arrow EZ-IO Needle has received FDA clearance for MR Conditional labeling, marking it as the first intraosseous needle to achieve this status. This development allows medical practitioners to maintain vascular access for patients requiring MRI scans without interruption. The EZ-IO Needle is designed for quick and accurate insertion, particularly in situations where traditional intravenous access is challenging. Teleflex aims to enhance patient care and expand the use of its medical devices through this innovation.
Read more →TFXTeleflex Awarded Agreements with Premier, Inc.
Teleflex Incorporated has announced the award of two group purchasing agreements with Premier, Inc., effective July 1, 2023. These agreements allow Premier members to leverage pre-negotiated pricing and terms for Teleflex's vascular access products, including Central Venous and Arterial Vascular Access items. The agreements include national deals for Hemodynamic Monitoring Products and Central Venous Access, helping streamline patient care and reduce infection risks. This aligns with Teleflex's ongoing commitment to innovation in medical technology.
Read more →TFXTeleflex Publishes 2022 Global Impact Report
WAYNE, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2022 Global Impact Report. The report outlines recent accomplishments and sets new targets to support the compan
Read more →TFXTeleflex Reports First Quarter Financial Results and Full Year 2023 Outlook
WAYNE, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended April 2, 2023. First quarter financial summary Revenues of $710.9 million, inclusive of five extra shipping days year-ove
Read more →TFXTeleflex Launches New Arrow VPS Rhythm DLX Device and NaviCurve™ Stylet in the United States
WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the launch of two new devices designed to enhance PICC insertion procedures and reduce the chance of complications. The new Arrow® VP
Read more →TFXTeleflex to Present at the Bank of America Securities 2023 Health Care Conference
WAYNE, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Securities 2023 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 9, 2023, at 10:
Read more →TFXTeleflex Announces First Quarter 2023 Earnings Conference Call Information
WAYNE, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 4, 2023. To participate in the conference call,
Read more →TFXTeleflex Selects GORE SEAMGUARD Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS Stapler
WAYNE, Pa., March 29, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced a supply agreement with W. L. Gore & Associates, Inc. (Gore) to use Gore’s GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement
Read more →TFXTeleflex to Present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum: Virtual
WAYNE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 12:00
Read more →TFXTeleflex Reports Fourth Quarter and Full Year 2022 Financial Results
WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2022. Fourth quarter financial summary Revenues of $758.0 million, down 0.5% compared to the prior year pe
Read more →TFXTeleflex Expands Interventional Cardiology Portfolio with Two New FDA-Cleared Catheter Devices for Use in Complex Percutaneous Coronary Interventions (PCI)
WAYNE, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced key milestones in the release of two new catheters: the U.S. Food and Drug Administration (FDA) 510(k) clearance of the Triumph™ Cat
Read more →TFXTeleflex to Present at the 44th Annual Raymond James Institutional Investors Conference
WAYNE, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 44th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, Ma
Read more →TFXTeleflex Announces Fourth Quarter 2022 Earnings Conference Call Information
WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 23, 2023. To participate in the conference
Read more →TFXTeleflex Launches National Ad Campaign — “Pit Stop” — to Raise Awareness of the UroLift System as a Treatment for Enlarged Prostate
WAYNE, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the launch of a new national advertising campaign to raise awareness of the UroLift® System, the leading minimally invasive, outpati
Read more →TFXTeleflex to Present at the 41st Annual J.P. Morgan Healthcare Conference
WAYNE, Pa., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 1
Read more →TFXTeleflex Celebrates 400,000 Patients Treated With the Minimally Invasive UroLift System
WAYNE, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that 400,000 patients have now been treated with the UroLift® System,1 a safe, effective and minimally invasive treatment option for
Read more →TFXTeleflex Earns Top Spot in MedReps Best Places to Work 2023 Ranking
WAYNE, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced it was named a MedReps.com 2023 Best Places to Work, earning the Number 1 spot for large companies and making this the sixth con
Read more →TFXTeleflex to Present at the 34th Annual Piper Sandler Healthcare Conference
WAYNE, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 34th Annual Piper Sandler Healthcare Conference at The Lotte New York Palace, New York, NY, on Wednesday, November 30, 2022 at 1:
Read more →TFXTeleflex Announces Worldwide Recall of Gibeck Iso-Gard Filter
WAYNE, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a worldwide recall of affected lots of the below-referenced Gibeck® Iso-Gard® Filter products. The Gibec
Read more →TFXTeleflex Reports Third Quarter Financial Results And Full Year Outlook
WAYNE, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 25, 2022. Third quarter financial summary Revenues of $686.8 million, down 1.9% year-over-year; up 2.4% on a c
Read more →TFXTeleflex Announces Third Quarter 2022 Earnings Conference Call Information
WAYNE, Pa., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 27, 2022. To participate in the conference c
Read more →TFXTeleflex Completes Acquisition of Standard Bariatrics
WAYNE, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Standard Bariatrics, Inc., which has commercialized an innovative pow
Read more →TFXTeleflex launches new Arrow Pressure Injectable Midline Catheter Portfolio
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) releases their new Arrow® Pressure Injectable Midline portfolio in the US and Canada, designed to help alleviate line identification confusion. Clinicians can choose between the Arrowg+ard Blue Advan
Read more →TFXTeleflex to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
WAYNE, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York, on Wednesday, September 14, 2022 at 10:00 a.m.
Read more →TFXTeleflex Announces Collaboration with FundamentalVR, to Improve Training Through Virtual Reality Simulation
FundamentalVR Offers Teleflex a Scalable Training Platform to Accelerate the Effective Use of the UroLift® 2 System for Treatment of Enlarged Prostate WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologi
Read more →TFXTeleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery
WAYNE, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has entered into a definitive agreement to acquire Standard Bariatrics, Inc. which has commercialized an innovative powered stapl
Read more →TFXTeleflex awarded Central Venous Access contract from Vizient
WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has been awarded a contract for the supply of Central Venous Access products from Vizient, Inc., the nation’s largest member-driven healthcare perfo
Read more →TFXTeleflex Publishes 2021 Global Impact Report
WAYNE, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has published its 2021 Global Impact Report. The report outlines recent accomplishments and organizational changes to suppor
Read more →TFXTeleflex Reports Second Quarter Financial Results And Full Year Outlook
WAYNE, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 26, 2022. Second quarter financial summary Revenues of $704.5 million, down 1.3% year-over-year; up 2.3% on a cons
Read more →TFXTeleflex Announces Pocono Raceway NASCAR Event to Raise Visibility of Enlarged Prostate and the Importance of Regular Health Screenings
WAYNE, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the company is hosting a booth at the Pocono Raceway NASCAR event in Long Pond, Pa., July 22-24, to raise awareness of benign p
Read more →TFXTeleflex Announces Second Quarter 2022 Earnings Conference Call Information
WAYNE, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 28, 2022. To participate in the conference cal
Read more →TFXTeleflex Announces First Patient Enrollment in MANTA Ultra Study
WAYNE, Pa., June 22, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical study that is intended to demonstrate the safety of MANTA® Vascular Closure Device ultras
Read more →TFXTeleflex launches new Arrow Pressure Injectable Midline Catheter in Australia and New Zealand
WAYNE, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Australia and New Zealand. The addition of the pressure injectabl
Read more →TFXTeleflex launches new Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region
WAYNE, Pa., June 07, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region. The addition of the pr
Read more →TFXTeleflex Celebrates June Men’s Health Month with Launch of UroLift Patient Ambassador Program
WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it is celebrating Men’s Health Month with the launch of the UroLift Patient Ambassador Program, a network of volunteers availab
Read more →TFXTeleflex Hosts 2022 Analyst & Investor Day
WAYNE, Pa., May 20, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, will provide an update on its business and address its 2023-2025 business growth strategy and financial goals during its 2022 Analyst & Investor Day today
Read more →TFXTeleflex Announces Regulatory Clearance for its UroLift System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)
WAYNE, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has received National Medical Products Administration (NMPA) approval for its UroLift® System in China for treating benign pr
Read more →TFXTeleflex Announces Health Canada Approval of MANTA Vascular Closure Device
WAYNE, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA® Vascular Closure Device – the first commercially available biomechanical v
Read more →TFXTeleflex Announces Full U.S. Commercial Launch of the UroLift 2 System and UroLift ATC Advanced Tissue Control System
WAYNE, Pa., May 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the full U.S. commercial launch of its UroLift® 2 System and UroLift ATC® System, and that it will update the urology community throu
Read more →TFXTeleflex to Host Analyst & Investor Day on May 20, 2022
WAYNE, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced that the Company will host an Analyst & Investor Day on Friday, May 20, 2022 in New York City. Liam Kelly, Chairman, President and CEO, will be joined by members of the
Read more →TFXTeleflex Reports First Quarter Financial Results And Full Year Outlook
WAYNE, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 27, 2022. First quarter financial summary Revenues of $641.7 million, up 1.2% year-over-year; up 3.2% on a consta
Read more →TFXTeleflex Named to Forbes Best Employers for Diversity 2022 List
WAYNE, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been named to the Forbes Best Employers for Diversity 2022 list. This prestigious award is presented by Forbes and Statista
Read more →TFXTeleflex to Present at the Bank of America Securities 2022 Healthcare Conference
WAYNE, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Securities 2022 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 10, 2022, at 11:
Read more →TFXTeleflex Announces First Quarter 2022 Earnings Conference Call Information
WAYNE, Pa., April 14, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter 2022 results, and provide an operational update at 8:00 a.m. Eastern Time on Thursday, April 28, 2022. To register for the conference call and
Read more →TFXTeleflex Announces the Launch of the UroLift System in Japan for the Treatment of Benign Prostatic Hyperplasia (BPH)
WAYNE, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced the launch of the UroLift System in Japan for treating benign prostatic hyperplasia (BPH), or enlarged prostate. The UroLift System i
Read more →TFXTeleflex to Present at the KeyBanc Life Sciences & MedTech Investor Forum
WAYNE, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022 at 9:45 a.m. (ET). A li
Read more →TFXTeleflex to Present at the 43rd Annual Raymond James Institutional Investors Conference
WAYNE, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 43rd Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, M
Read more →TFXDocument
Teleflex Announces Fourth Quarter and Full-Year 2021 Financial Results Wayne, PA -- Teleflex Incorporated (NYSE TFX) (the "Company") today announced financial results for the fourth quarter ended December 31, 2021. Fourth quarter financial summary Reported revenues of $761.9 m
Read more →TFXTeleflex Announces Fourth Quarter and Full-Year 2021 Financial Results
WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2021. Fourth quarter financial summary Reported revenues of $761.9 million, up 7.1% year-over-year; up 7.9
Read more →TFXTeleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures
WAYNE, Pa., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for its specialty catheters and coronary guidewi
Read more →TFXTeleflex Announces Fourth Quarter and Full Year 2021 Earnings Conference Call Information
WAYNE, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 24, 2022. To register f
Read more →TFXTeleflex to Present at the 40th Annual J.P. Morgan Healthcare Conference
WAYNE, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. (ET). A live audio webcast of the confer
Read more →TFXTeleflex Receives Reimbursement Approval for the UroLift System in Japan
WAYNE, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that the company has received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo) of its UroLift System for patients who require treatment for b
Read more →TFXTeleflex Incorporated Announces Worldwide Recall of Arrow-Trerotola™ Over-The-Wire PTD Kit Percutaneous Thrombolytic Device: 7FR
WAYNE, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a worldwide recall of Arrow-Trerotola™ Over-The-Wire PTD® Kit Percutaneous Thrombolytic Device: 7FR. The
Read more →TFXTeleflex Earns Top Spot in MedReps Best Places to Work 2022 Ranking
WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced it was named a winner in the MedReps.com Best Places to Work in Medical Sales 2022 survey, earning the Number 1 spot for large compani
Read more →TFXTeleflex to Participate in the 33rd Annual Virtual Piper Sandler Healthcare Conference
WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and CFO, Teleflex Incorporated (NYSE: TFX), is pleased to participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. From November 22nd to December 2nd, 2021, registered attende
Read more →TFXTeleflex Integrates Medical Education and Training with Explorer Surgical to Expand Urologists’ Access to Procedural Expertise
WAYNE, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced it is combining its leading industry clinical education with the digital platform of Explorer Surgical, a GHX company. This collaborat
Read more →TFXTeleflex Comments on the Centers for Medicare & Medicaid Services 2022 Medicare Physician Fee Schedule Final Rule
WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies today commented on the recently released Centers for Medicare & Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Fin
Read more →TFXTeleflex Reports Third Quarter 2021 Results and Full Year Outlook
WAYNE, Pa., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 26, 2021. Third quarter financial summary Reported revenues of $700.3 million, up 11.5% year-over-year; up 10.
Read more →TFXTeleflex Completes Enrollment in Cardiac IDE Study
WAYNE, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of the QuikClot Control+® Hemostatic Device for
Read more →TFXTeleflex Announces Third Quarter 2021 Earnings Conference Call Information
WAYNE, Pa., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 28, 2021. To register for the conference cal
Read more →TFXTeleflex Announces Large-Scale Analysis of Real-World Healthcare Claims Data for Enlarged Prostate Procedures at the American Urological Association 2021 Annual Meeting
WAYNE, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift® System among the analyzed benign prostatic hyperplasia
Read more →TFXTeleflex Unveils the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System and Real-World Data Presentations at the American Urological Association 2021 Annual Meeting
New real-world data findings along with new product evolutions demonstrate why the UroLift® System is the right solution for most BPH patients WAYNE, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that two new UroLift System products, t
Read more →TFXTeleflex to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
WAYNE, Pa., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021 at 8:00 a.m. (ET). A live audio webcas
Read more →TFXTeleflex to Present at the Wells Fargo 2021 Virtual Healthcare Conference
WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo 2021 Virtual Healthcare Conference on Thursday, September 9, 2021 at 12:40 p.m. (ET). A live audio webcast of the co
Read more →TFXTeleflex Reports Second Quarter 2021 Results and Full Year Outlook
WAYNE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 27, 2021. Second quarter financial summary Reported revenues of $713.5 million, up 25.8% year-over-year; up 21.0%
Read more →TFXLawrence Keusch Vice President, Investor Relations and Strategy Development 610-948-2836
TELEFLEX REPORTS SECOND QUARTER 2021 RESULTS AND FULL YEAR OUTLOOK Wayne, PA -- Teleflex Incorporated (NYSE TFX) (the "Company") today announced financial results for the second quarter ended June 27, 2021. Second quarter financial summary Reported revenues of $713.5 million,
Read more →TFXTeleflex Announces Second Quarter 2021 Earnings Conference Call Information
WAYNE, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 29, 2021. To register for the conference call
Read more →TFXTeleflex Announces Real-World Clinical Data Presentations of the UroLift System at the 36th Annual European Association of Urology Congress
WAYNE, Pa., July 06, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that new data from real-world clinical studies of the UroLift® System for men with benign prostatic hyperplasia (BPH) will be presented at the 36th European Association of Urology (EAU)
Read more →TFXTeleflex Completes Divestiture of Respiratory Assets to Medline Industries
WAYNE, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Today, Teleflex Incorporated (NYSE:TFX), a leading global provider for healthcare supplies and services, announced it has completed the previously announced divestiture of a significant portion of its Respiratory business to Medline I
Read more →TFXTeleflex to Present at the Raymond James 2021 Human Health Innovation Conference
WAYNE, Pa., June 07, 2021 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 2021 Human Health Innovation Conference on Monday, June 21, 2021 at 8:40 a.m. (ET). A
Read more →TFXTeleflex Signs Definitive Agreement to Sell Certain Respiratory Assets and Reaffirms Adjusted EPS Guidance
Total consideration is $286 million, reduced by $12 million of working capital to be retained by Teleflex Assets to be divested generated $139M in 2020 revenue, with 2021 growth expected to be approximately flat 2021 headwinds are estimated at $28-32 million in revenue and $0.1
Read more →TFXTeleflex to Present at the UBS Global Healthcare Virtual Conference
WAYNE, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- May 11, 2021 – Thomas Powell, Executive Vice President and CFO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021 at 3:00 p.m. (ET). A live audio webcast
Read more →TFXJake Elguicze Treasurer and Vice President of Investor Relations 610-948-2836
TELEFLEX REPORTS FIRST QUARTER 2021 RESULTS First quarter 2021 revenues of $633.9 million, up 0.5% versus prior year period on an as-reported basis down 2.6% on a constant currency basis First quarter 2021 GAAP diluted EPS from continuing operations of $1.58, compared to $2.78
Read more →TFXTeleflex Reports First Quarter 2021 Results
First quarter 2021 revenues of $633.9 million, up 0.5% versus prior year period on an as-reported basis; down 2.6% on a constant currency basis First quarter 2021 GAAP diluted EPS from continuing operations of $1.58, compared to $2.78 in the prior year period First quarter 2021
Read more →TFXTeleflex to Present at the Bank of America Securities 2021 Virtual Health Care Conference
WAYNE, Pa., April 27, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. (ET). A live audio webcast
Read more →TFXTeleflex Announces First Quarter 2021 Earnings Conference Call Information
WAYNE, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the first quarter 2021 will be released before market open on Thursday, April 29, 2021. An investor conference call will be held at 8:00 a.m. (ET) on Thurs
Read more →TFXTeleflex to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
WAYNE, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Jake Elguicze, Treasurer and Vice President of Investor Relations, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 24, 2021 at 9:15am
Read more →TFXTeleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift System
WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift® System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH). In the United State
Read more →TFXTeleflex Reports Fourth Quarter and Full Year 2020 Results; Provides 2021 Guidance
Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basis Fourth quarter 2020 GAAP diluted EPS from continuing operations of $1.62, compared to $2.28 in the prior year period Fourth quarter 202
Read more →TFXTeleflex Announces Submission of Biologics License Application for Its Investigational Freeze Dried Plasma
WAYNE, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) fo
Read more →TFXTeleflex to Present at Barclays Global Healthcare Conference
WAYNE, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 10:55 am (ET). A live audio webcast of the conference presentatio
Read more →TFXTeleflex Completes Enrollment in CTO-PCI IDE Study
WAYNE, Pa., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of Teleflex specialty catheters and coronary gui
Read more →TFXTeleflex Named One of America’s Best Employers 2021 by Forbes
WAYNE, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), has been recognized as part of Forbes’ list of America’s Best Employers 2021. The company ranked #26 out of 500 employers in the Mid-Sized Employers category and #2 in the Health Care Equipment & Ser
Read more →TFXTeleflex to Present at the Raymond James 42nd Annual Institutional Investors Conference
WAYNE, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 42nd Annual Institutional Investors Conference on Tuesday, March 2, 2021 at 12:30 p.m. (ET). A live audio webcast
Read more →TFXTeleflex Announces Fourth Quarter and Full Year 2020 Earnings Conference Call Information
WAYNE, Pa., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the fourth quarter and full year 2020 will be released before market open on Thursday, February 25, 2021. An investor conference call will be held at 8:00 a.
Read more →TFXTeleflex continues to deliver COMPLETE confidence with new Arrow ErgoPack Complete MAC, PSI Systems
WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) continues to deliver COMPLETE confidence with the release of the Arrow® ErgoPack® Complete Multi-Lumen Access Catheter (MAC) System and the Arrow® ErgoPack® Complete Percutaneous Sheath Introducer (PS
Read more →TFXTeleflex to Present at the 39th Annual J.P. Morgan Healthcare Conference
WAYNE, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 8:20 a.m. (ET). A live audio webcast of the confer
Read more →TFXTeleflex Completes Acquisition of Market Leader in Hemostatic Products
WAYNE, Pa., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider for healthcare supplies and services, announced today that it has completed the previously announced acquisition of Z-Medica, LLC, an industry-leading manufacturer of hemosta
Read more →TFXTeleflex Ranked a Best Place to Work 2021 by MedReps.com
WAYNE, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that it was named the winner of MedReps.com’s 10th Annual Best Places to Work in Medical Sales 2021 survey for the Large Category Best Medical Device Companies and placed second in the
Read more →TFXTeleflex to Present at the Stephens Investment Conference 2020
WAYNE, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Stephens Investment Conference 2020, on Monday, November 16, 2020 at 1:00 p.m. (ET). A live audio webcast of the conference pres
Read more →TFXTeleflex Reports Third Quarter 2020 Results
Third Quarter Revenues of $628.3 million, down 3.1% versus Prior Year Period on an As-Reported basis; down 4.1% on a Constant Currency basis Third Quarter GAAP Diluted EPS from Continuing Operations of $2.46, Compared to $4.85 in the Prior Year Period Third Quarter Adjusted Dil
Read more →TFXTeleflex to Acquire Market Leader in Hemostatic Products
WAYNE, Pa., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider for healthcare supplies and services, today announced it has entered into a definitive agreement to acquire privately-held Z-Medica, LLC, an industry-leading manufacturer of
Read more →TFXTeleflex Interventional Urology Expands Portfolio with Introduction of the UroLift Advanced Tissue Control (ATC)™ System
WAYNE, Pa., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the expansion of its UroLift® System portfolio with the introduction of the UroLift® Advanced Tissue Control (ATC)™ System. The new system, which builds on the highly successful UroLif
Read more →TFXTeleflex Delivers COMPLETE Confidence with the New Arrow ErgoPack Complete CVC System
WAYNE, Pa., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) delivers COMPLETE confidence to central line inserters with the release of the Arrow® ErgoPack® Complete CVC System, the most important update to its market-leading1 portfolio of Centrally-Inserted Ce
Read more →TFXTeleflex Announces Third Quarter 2020 Earnings Conference Call Information
WAYNE, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the third quarter 2020 will be released before market open on Thursday, October 29, 2020. An investor conference call will be held at 8:00 a.m. (ET) on Thurs
Read more →TFXTeleflex Named One of America’s Best-In-State Employers 2020 by Forbes
WAYNE, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), has been recognized as part of Forbes’ annual list of America’s Best-In-State Employers 2020. The company ranked #6 out of 100 employers in the state of Pennsylvania. This prestigious award is presen
Read more →TFXTeleflex Announces Expanded Indications for the Arrow EZ-IO Intraosseous Vascular Access System
WAYNE, Pa., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the Indications f
Read more →TFXTeleflex to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
WAYNE, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 2:00 p.m. (ET). A live audio webcas
Read more →TFXTeleflex to Present at the Wells Fargo 2020 Virtual Healthcare Conference
WAYNE, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 12:40 p.m. (ET). A live audio webcast of the c
Read more →TFXTeleflex Publishes 2nd Annual Global JOIN Impact Report
WAYNE, Pa., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), today announced the publication of its 2nd annual Global JOIN Impact Report. The report outlines the progress the company made in 2019 in the areas of people, environmental sustainability with a focu
Read more →TFXTeleflex Reports Second Quarter 2020 Results
Second Quarter Revenues of $567.0 million, down 13.1% versus Prior Year Period; down 12.0% on a Constant Currency Basis Second Quarter GAAP Diluted EPS from Continuing Operations of $0.24, Compared to $1.77 in the Prior Year Period Second Quarter Adjusted Diluted EPS from Conti
Read more →TFXTeleflex Announces 200,000 Patients Treated with UroLift System for Enlarged Prostate
WAYNE, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that 200,000 patients have been treated with the minimally invasive UroLift® System for benign prostatic hyperplasia (BPH) worldwide. Affecting more than 40 million men in the United
Read more →TFXTeleflex Announces Positive Data Emphasizing the Effectiveness of the UroLift System Treatment for Enlarged Prostate Across Broad Patient Populations
Data Presented at European Association of Urology Highlights Safety and Versatility of the Minimally Invasive UroLift System in a Real-World Setting WAYNE, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that data from three studies of th
Read more →TFXTeleflex Announces Second Quarter 2020 Earnings Conference Call Information
WAYNE, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the second quarter 2020 will be released before market open on Thursday, July 30, 2020. An investor conference call will be held at 8:00 a.m. (ET) on Thursd
Read more →TFXTeleflex COVID 19 Humanitarian Product Donation Program
WAYNE, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced an online submission portal for its COVID‑19 Humanitarian Product Donation Program. As a global healthcare company operating in cou
Read more →TFXTeleflex Announces Publication of Early Patient Experience Data Highlighting the UroLift System as a Superior Treatment to Rezum™ Steam Injection in Patients with Enlarged Prostate
Data Shows Minimally Invasive Treatment Provides Rapid Symptom Relief, Allowing Men to Return to Daily Activities Quickly WAYNE, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of data from a study comparing patient experi
Read more →TFXTeleflex to Present at the Raymond James 2020 Human Health Innovation Conference
WAYNE, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 2020 Human Health Innovation Conference on Wednesday, June 17, 2020 at 2:20 p.m. (ET).
Read more →TFXTeleflex Announces First Patient Enrollment in CTO-PCI IDE Study
WAYNE, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical study that will evaluate the performance of Teleflex coronary guidewires and specialty ca
Read more →TFXJake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 FOR IMMEDIATE RELEASE TELEFLEX INCORPORATED ANNOUNCES PRICING OF $500
Contact: Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 TELEFLEX INCORPORATED ANNOUNCES PRICING OF $500 MILLION SENIOR NOTES OFFERING WAYNE, Pa. May 21, 2020 Teleflex Incorporated (NYSE: TFX) ( Teleflex ) announced today that it priced its priv
Read more →TFXTeleflex Incorporated Announces Private Offering of $500 Million of Senior Notes due 2028
WAYNE, Pa., May 21, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2028 (the “Notes”), subject to market and other conditions. The inte
Read more →TFXTeleflex Announces Positive Data Showing that the UroLift System Effectively Relieves Enlarged Prostate Symptoms While Preserving Patients’ Sexual Function*
Data Presented at American Urological Association 2020 Virtual Experience Highlight Benefits and Superior Sexual Function* Preservation of the Minimally Invasive Treatment for Patients with Enlarged Prostate WAYNE, Pa., May 18, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYS
Read more →TFXTeleflex to Present at the UBS Virtual Global Healthcare Conference
WAYNE, Pa., May 04, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 10:50 a.m. (ET). A live audio webcast of the conference presentation, a
Read more →TFXTeleflex Reports First Quarter 2020 Results
First Quarter 2020 Revenues of $630.6 million, up 2.8% Versus Prior Year Period; up 4.0% on a Constant Currency Basis First Quarter 2020 GAAP Diluted EPS from Continuing Operations of $2.78, up 212.4% Versus Prior Year Period First Quarter 2020 Adjusted Diluted EPS from Continu
Read more →TFXTeleflex awarded Central Venous Access, Arterial Access agreements with Premier
WAYNE, Pa., April 29, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has been awarded group purchasing agreements for Central Venous Access and Arterial Access with Premier, effective Ju
Read more →TFXTeleflex to Present at the Bank of America Merrill Lynch 2020 Health Care Conference
WAYNE, Pa., April 29, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, 2020 at 4:20 p.m. (ET). A live audio webcast of the confe
Read more →TFXTELEFLEX ANNOUNCES FIRST QUARTER 2020 EARNINGS CONFERENCE CALL INFORMATION
Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, April 30, 2020 WAYNE, Pa., April 20, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the first quarter 2020 will be released before market open on Thursday, April 30, 2
Read more →TFXTeleflex Announces 2020 Annual Meeting of Stockholders to be Held in Virtual-Only Format
WAYNE, Pa., April 17, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting”) will be conducted exclusively online by remote communication due to public health concerns regarding COVID-19 and g
Read more →TFXTeleflex Celebrates 175,000 Patients Treated with the UroLift System
Minimally Invasive Treatment for Enlarged Prostate Provides Rapid Relief1and Durable Results2 WAYNE, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that 175,000 patients have now been treated globally* with its minimally invasive UroLif
Read more →TFXTeleflex Reports Fourth Quarter and Full Year 2019 Results; Provides 2020 Guidance
Fourth Quarter 2019 Revenues of $681.0 million, up 6.1% Versus Prior Year Period; up 7.1% on a Constant Currency Basis Fourth Quarter 2019 GAAP Diluted EPS from Continuing Operations of $2.28, up 21.9% Versus Prior Year Period Fourth Quarter 2019 Adjusted Diluted EPS from Conti
Read more →TFXTeleflex to Present at the Raymond James 41st Annual Institutional Investors Conference
WAYNE, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 41st Annual Institutional Investors Conference at the JW Marriott Grande Lakes in Orlando, Florida on Tuesday, March 3, 2020
Read more →TFXTeleflex Incorporated Announces Worldwide Voluntary Recall of COMFORT FLO Humidification System
WAYNE, Pa., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies for critical care and surgery, has announced a worldwide voluntary recall of the COMFORT FLO® Humidification System. The recalled products provide a continu
Read more →TFXTeleflex to Present at the 9th Annual SVB Leerink Global Healthcare Conference
WAYNE, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at the 9th Annual SVB Leerink Global Healthcare Conference at the Lotte New York Palace Hotel in New York, NY, on Thursday, February 27, 2020 at 10
Read more →TFXTeleflex Announces Fourth Quarter and Full Year 2019 Earnings Conference Call Information
WAYNE, Pa., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the fourth quarter and full year 2019 will be released before market open on Thursday, February 20, 2020. An investor conference call will be held at 8:00 a
Read more →TFXTeleflex Receives FDA Clearance for Wattson™ Temporary Pacing Guidewire
WAYNE, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration for the WattsonTM Tempora
Read more →TFXTeleflex Convenes Urologists in Australia for Summit on Treating Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
Minimally Invasive UroLift® System Provides Safe and Effective Symptom Relief for Men with an Enlarged Prostate While Preserving Sexual Function* WAYNE, Pa., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) recently hosted urologists from around the world to r
Read more →TFXTeleflex Announces FDA Clearance for Expanded Indication of the UroLift System for Treatment of Larger Prostates, Up to 100cc
WAYNE, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that the U.S. Food and Drug Administration (FDA) has granted the company an expanded indication for the use of its UroLift® System to treat larger prostates, between 80cc and100cc. Thi
Read more →TFXTeleflex to Present at the 38th Annual J.P. Morgan Healthcare Conference
WAYNE, Pa., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 14, 2020 at
Read more →TFXTeleflex to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top
WAYNE, Pa., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top conference at the Goldman Sachs Office in New York, NY, on Thursd
Read more →TFXTeleflex Ranked a Best Place to Work by MedReps.com
WAYNE, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announced that it was named the winner of MedReps.com’s 9th Annual Best Places to Work 2020 survey for the Large Categ
Read more →TFXTeleflex to Present at the 31st Annual Piper Jaffray Healthcare Conference
WAYNE, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 31st Annual Piper Jaffray Healthcare Conference at The Lotte New York Palace Hotel, in New York City, on Thursday, December 5, 2019 at 9:00
Read more →TFXTeleflex to Showcase its Interventional Portfolio Highlighting the MANTA Vascular Closure Device and the Langston Dual Lumen Catheters at the PCR London Valves 2019
WAYNE, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will showcase its Interventional product portfolio including the MANTA® Vascular Closure Device and Langston® Dual Lumen Catheters at the PCR London
Read more →TFXTeleflex to Present at the Stephens Nashville 2019 Investment Conference
WAYNE, Pa., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Stephens Nashville 2019 Investment Conference at the Omni Nashville Hotel in Nashville, TN, on Thursday, November 14, 2019 at 9:00 a.m. (CT
Read more →TFXTeleflex Reports Third Quarter 2019 Results
Third Quarter Revenues from Continuing Operations of $648.3 million, up 6.3% versus the Prior Year Period; up 8.0% on a Constant Currency Basis Third Quarter GAAP Diluted EPS from Continuing Operations of $4.85, up 300.8% Versus the Prior Year Period Third Quarter Adjusted Dilu
Read more →TFXTeleflex Announces Third Quarter 2019 Earnings Conference Call Information
WAYNE, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the third quarter 2019 will be released before market open on Thursday, October 31, 2019. An investor conference call will be held at 8:00 a.m. (ET) on Thur
Read more →TFXTeleflex Incorporated Announces Worldwide Voluntary Recall of GaleMed Corporation (third party manufacturer) Babi.Plus 12.5 cm H2O Pressure Relief Manifold
WAYNE, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), announced a recall June 14th, 2019 of certain lots of the GaleMed (third party manufacturer) Babi.Plus® 12.5 cm H2O Pressure Relief Manifold. Teleflex receives the product from the manufacturer GaleM
Read more →TFXTeleflex Announces Tenth Anniversary of GuideLiner Catheter Product Line
WAYNE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the tenth anniversary of its industry-leading GuideLiner® Catheter. Released in November 2009, the GuideLiner® Catheter revolution
Read more →TFXTeleflex Announces Urology Times Article Highlighting the UroLift System as Providing a Superior Patient Experience for Treating Enlarged Prostate
WAYNE, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of an article showcasing the effectiveness and overall benefits of the minimally invasive UroLift® System treatment for patients with benign prostatic hyperplasia (BPH
Read more →TFXTeleflex to Support Responding to Cardiac Arrest at ERC Congress 2019, in Ljubljana, Slovenia from September 19th – 21st
WAYNE, Pa., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will focus on its Arrow® EZ-IO® Intraosseous Access System and on the campaigns “What could 10 seconds to vascular access mean to your cardiac arre
Read more →TFXTeleflex to Showcase its Peripheral Intervention Product Portfolio Highlighting the Arrow OnControl Powered Bone Access System and the MANTA™ Vascular Closure Device at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2019
WAYNE, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will showcase its Peripheral Intervention product portfolio including the Arrow® OnControl® Powered Bone Access System and the MANTA™ Vascular Closu
Read more →TFXTeleflex to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
WAYNE, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 17th Annual Global Healthcare Conference at the Grand Hyatt in New York City, Wednesday, September 11, 2019 at 11:05 a.m. (E
Read more →TFXTeleflex to Present at the Wells Fargo Securities 2019 Healthcare Conference
WAYNE, Pa., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo Securities 2019 Healthcare Conference at the Westin Copley Place in Boston, MA, Wednesday, September 4, 2019 at 9:40 a.m. (ET).
Read more →TFXTeleflex Wins New Zealand Innovation Award for UroLift System for Patients with Enlarged Prostate
Minimally Invasive Treatment Provides Rapid, Durable Symptom Relief Without Compromising Sexual Function* WAYNE, Pa., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the UroLift® System, a proven, minimally invasive treatment for patients with
Read more →TFXTeleflex Reports Second Quarter 2019 Results
Second Quarter Revenues from Continuing Operations of $652.5 million, up 7% versus Prior Year Period; up 9.6% on a Constant Currency Basis Second Quarter GAAP Diluted EPS from Continuing Operations of $1.77, Compared to ($0.06) in the Prior Year Period Second Quarter Adjusted D
Read more →TFXTeleflex Announces Publication of “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device”
WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of the “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device.” The SAFE MANTA IDE Clinical Trial, the large
Read more →TFXTeleflex Announces Second Quarter 2019 Earnings Conference Call Information
WAYNE, Pa., July 18, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the second quarter 2019 will be released before market open on Thursday, August 1, 2019. An investor conference call will be held at 8:00 a.m. (ET) on Thurs
Read more →TFXTeleflex Announces Publication of a Large Real-World Study Confirming Results from Controlled Clinical Studies of the UroLift System
WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of positive results from a multi-center study reaffirming the safety and effectiveness of the minimally invasive UroLift® System for the treatment of benign prostatic h
Read more →TFXTeleflex Announces Expanded Nationwide Coverage for the UroLift System for Patients with Enlarged Prostate
WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that Anthem®, one of the nation’s leading health insurance providers is now covering the UroLift® System, a proven, minimally invasive treatment for men with benign prostatic hyperplas
Read more →TFXTeleflex Incorporated Announces Worldwide Voluntary Recall of Select Hudson RCI Sheridan Endotracheal Tubes
WAYNE, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), has announced a worldwide recall of certain lots of Hudson RCI® Sheridan® Endotracheal Tubes. The recalled products are designed for oral or nasal intubation and are indicated for airway management.
Read more →TFXTeleflex to Present at the Raymond James Life Sciences and MedTech Conference
WAYNE, Pa., June 05, 2019 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James Life Sciences and MedTech Conference at the Lotte New York Palace, New York, NY, on Wed
Read more →TFXTeleflex to Present at the 40th Annual Goldman Sachs Global Healthcare Conference
WAYNE, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 40th Annual Goldman Sachs Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, Ca
Read more →TFXTeleflex to participate at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) 2019 with its complex PCI product portfolio and the newly acquired MANTA™ Vascular Closure Device
WAYNE, Pa., May 15, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, coronary and peripheral interventions, will showcase its complex PCI product portfolio, the Arrow® AC3 Optimus
Read more →TFXTeleflex Announces Positive Results from Five Studies Underscoring the Effectiveness and Versatility of the UroLift System Treatment for BPH
WAYNE, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the presentation of new clinical data at the American Urological Association (AUA) 2019 Annual Meeting from five studies of the UroLift® System for patients with benign prostatic hyperp
Read more →TFXTeleflex Reports First Quarter 2019 Results
First Quarter Revenues from Continuing Operations of $613.6 million, up 4.5% versus Prior Year Period; up 7.6% on a Constant Currency Basis First Quarter GAAP Diluted EPS from Continuing Operations of $0.89, down 24.6% versus Prior Year Period First Quarter Adjusted Diluted EPS
Read more →TFXTeleflex Announces Multiple Data Presentations from Studies of the UroLift System Treatment for Enlarged Prostate at the American Urological Association 2019 Meeting
WAYNE, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that new clinical data from numerous studies of the UroLift® System for patients with benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) 2
Read more →TFXTeleflex to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
WAYNE, Pa., April 30, 2019 (GLOBE NEWSWIRE) -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Merrill Lynch 2019 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 14, 2019 at 4:20 p.m.
Read more →TFXTeleflex Announces First Quarter 2019 Earnings Conference Call Information
WAYNE, Pa., April 18, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the first quarter 2019 will be released before market open on Thursday, May 2, 2019. An investor conference call will be held at 8:00 a.m. (ET) on Thursday
Read more →TFXTeleflex Publishes Inaugural Corporate Social Responsibility (CSR) Report
WAYNE, Pa., March 26, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced the publication of its inaugural corporate social responsibility report, The JOIN Impact Report. The re
Read more →TFXTeleflex Announces Real-World Data Demonstrating the Effectiveness of the UroLift System to Treat Patients with Enlarged Prostate
WAYNE, Pa., March 21, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that multiple studies were presented at the 2019 European Association of Urology (EAU) meeting in Barcelona, Spain, highlighting the effectiveness of the UroLift® System, a minimally i
Read more →TFXto22120198kresupple Schedule of Segment Revenues Three Months Ended % Increase / (Decrease)
Schedule of Segment Revenues Three Months Ended % Increase / (Decrease) April 1, 2018 April 2, 2017 Total Currency Constant Currency Americas $ 323.3 $ 260.8 24.0% 0.4% 23.6% EMEA 159.9 133.6 19.7% 15.1% 4.6% Asia 58.2 50.2 16.1% 7.0% 9.1% OEM 45.8 43.3 5.8% 2.9% 2.9% Net revenue
Read more →TFXJake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 Teleflex Incorporated Hosts Analyst & Investor Day Reaffirms 2018 Guidance and Provides 3-Year Financial Goals and Objectives Wayne, PA
Teleflex Incorporated Hosts Analyst & Investor Day Reaffirms 2018 Guidance and Provides 3-Year Financial Goals and Objectives Wayne, PA -- (BUSINESS WIRE) -- May 11, 2018 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, will provide an update
Read more →TFXJake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 FOR IMMEDIATE RELEASE TELEFLEX INCORPORATED ANNOUNCES PUBLIC OFFERING OF $500
Contact: Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 TELEFLEX INCORPORATED ANNOUNCES PUBLIC OFFERING OF $500 MILLION OF SENIOR NOTES WAYNE, Pa. November 16, 2017 Teleflex Incorporated (NYSE: TFX) ( Teleflex ) announced today the registered p
Read more →TFXTeleflex Enters Into Separate Privately Negotiated Agreements with Certain of its Convertible Note Holders WAYNE, Pa.
Teleflex Enters Into Separate Privately Negotiated Agreements with Certain of its Convertible Note Holders WAYNE, Pa.-December 15, 2016-Teleflex Incorporated (NYSE:TFX) announced today that it has entered into separate, privately negotiated agreements with certain of the holders
Read more →TFXTELEFLEX INCORPORATED TO ACQUIRE VASCULAR SOLUTIONS
TELEFLEX INCORPORATED TO ACQUIRE VASCULAR SOLUTIONS Significantly advances Teleflex's offering of vascular and interventional solutions Provides differentiated, high-growth and high-margin product offerings with demonstrable clinical benefits Compelling financial profile that
Read more →TFXTeleflex Incorporated Selects Widen Media Collective to Manage Digital Media Distribution
MADISON, WI--(Marketwired - May 17, 2016) - Teleflex Incorporated, a global provider of medical devices for critical care, urology and surgery, has selected the Widen Media Collective for its digital asset management (DAM) needs. With employees working around the world, the compa
Read more →TFXJake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 FOR IMMEDIATE RELEASE TELEFLEX INCORPORATED ANNOUNCES PUBLIC OFFERING OF $400
Contact: Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 TELEFLEX INCORPORATED ANNOUNCES PUBLIC OFFERING OF $400 MILLION OF SENIOR NOTES WAYNE, Pa. May 11, 2016 Teleflex Incorporated (NYSE: TFX) ( Teleflex ) announced today the registered public
Read more →TFXConference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for international calls
1 TELEFLEX INCORPORATED THIRD QUARTER 2015 EARNINGS CONFERENCE CALL 1 Exhibit 99.2 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or
Read more →TFXto22020158kreq 1 TELEFLEX INCORPORATED FOURTH QUARTER 2014 EARNINGS CONFERENCE CALL 1 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on "Inv
1 TELEFLEX INCORPORATED FOURTH QUARTER 2014 EARNINGS CONFERENCE CALL 1 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for interna
Read more →TFXConference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors ) Telephone replay available by dialing 888 286 8010 or for international calls,
Low High GAAP Operating Margin 15.8% 16.7% Losses and other charges 0.7% 0.8% Adjusted Operating Margin 16.5% 17.5% Intangible amortization expense 3.5% 3.5% Adjusted Operating Margin Excluding Intangible Amortization Expense 20.0% 21.0% Appendix K Reconciliation of 2014 Adjusted
Read more →TFXTELEFLEX INCORPORATED AND SUBSIDIARIES Segment Net Revenues Years Ended
TELEFLEX INCORPORATED AND SUBSIDIARIES Segment Net Revenues Years Ended December 31, 2011 2012 2013 Unaudited Vascular North America $ 214,822 $ 222,749 $ 231,112 Anesthesia/Respiratory North America 162,833 180,363 228,485 Surgical North America 1
Read more →TFXPROPOSAL 2: APPROVAL OF 2014 STOCK INCENTIVE PLAN On
2014 STOCK INCENTIVE PLAN On February 19, 2014, our Board, upon the recommendation of our Compensation Committee, approved the Teleflex Incorporated 2014 Stock Incentive Plan (the 2014 Plan ), subject to stockholder approval. We currently award stock options and restricted sto
Read more →TFXTELEFLEX INCORPORATED SECOND QUARTER 2013 EARNINGS CONFERENCE CALL 1 Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on Investors ) Telephone rep
TELEFLEX INCORPORATED EARNINGS CONFERENCE CALL Conference Call Logistics accompanying slides, and replay webcast available online at www.teleflex.com (click on Investors ) Telephone replay available by dialing 888-286-8010 or for international calls, 617-801-6888, pass code n
Read more →TFXConference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for international calls, 61
Adjusted operating income and margin exclude costs associated acquisitions, restructuring and impairment charges and (gain) loss on sale of businesses and assets. Reconciliation of these non-GAAP measures to the most comparable GAAP measures is contained within this presentation.
Read more →TFXTELEFLEX INCORPORATED FOURTH QUARTER FULL YEAR 2012EARNINGS CONFERENCE CALL 1 Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "Investors")Tele
Mexico to Czech RepublicAnnounced the closure of a distribution center in France 12 Full Year Strategic Highlights Completed mix of market-share enhancing and technology acquisitionsLMA International N.V. and affiliatesSemprus BioSciencesHotspur TechnologiesAxiom Technology Partn
Read more →TFX: Jake Elguicze Treasurer and Vice President of Investor Relations 610-948-2836
Treasurer and Vice President of Investor Relations TELEFLEX REPORTS FIRST QUARTER 2012 RESULTS Revenues Rise 9.5% to $387.8 million; up 10.9% Constant Currency GAAP EPS of ($6.97); $1.01 on Adjusted EPS basis Records Non Cash Impairment Charge Due to Reallocation of Goodwill
Read more →TFXThis presentation and our discussion contain forward-looking information and statements including, but not limited to, longer-term growth and profitability objectives over the next 5 years, including, achievement of cons
In 2011, the Company terminated our interest rate swap that, at the date of termination, had a notional amount of $350 million. The interest rate swap was designated as a cash flow hedge against the term loan under our senior credit facility. At the date of termination, the inter
Read more →TFXTELEFLEX INCORPORATED FOURTH QUARTER FULL YEAR 2011 2012 OUTLOOK EARNINGS CONFERENCE CALL 2 Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "I
The net of tax impact was approximately $7.0 million, or $0.17 per share. The tax adjustment represents a net benefit resulting from the resolution (including the expiration of statutes of limitations) of various U.S. federal, state and foreign tax matters relating to prior years
Read more →Competitive Position
How TFX ranks across every disease it competes inCompetitive Position is a premium feature
See how TFX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial